Bio-Techne (NASDAQ:TECH) Announces Quarterly Earnings Results

Bio-Techne (NASDAQ:TECH) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.03, FiscalAI reports. The company had revenue of $295.88 million for the quarter, compared to the consensus estimate of $290.20 million. Bio-Techne had a return on equity of 13.59% and a net margin of 6.41%.The firm’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter last year, the company earned $0.42 earnings per share.

Bio-Techne Trading Up 5.3%

Shares of TECH stock traded up $3.42 during trading hours on Wednesday, hitting $68.05. 534,639 shares of the company’s stock traded hands, compared to its average volume of 2,344,217. Bio-Techne has a 12 month low of $46.01 and a 12 month high of $79.28. The company has a quick ratio of 2.81, a current ratio of 4.22 and a debt-to-equity ratio of 0.15. The stock’s 50 day simple moving average is $63.15 and its 200 day simple moving average is $59.14. The stock has a market cap of $10.60 billion, a PE ratio of 138.74, a price-to-earnings-growth ratio of 4.50 and a beta of 1.48.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TECH. Measured Wealth Private Client Group LLC purchased a new stake in Bio-Techne in the third quarter worth about $32,000. iSAM Funds UK Ltd bought a new stake in shares of Bio-Techne during the third quarter valued at approximately $33,000. EverSource Wealth Advisors LLC raised its holdings in shares of Bio-Techne by 506.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 562 shares in the last quarter. Employees Retirement System of Texas bought a new stake in shares of Bio-Techne in the 3rd quarter valued at approximately $67,000. Finally, CIBC Private Wealth Group LLC boosted its stake in shares of Bio-Techne by 50.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,118 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 712 shares during the period. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

More Bio-Techne News

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Q2 results beat expectations: EPS $0.46 vs. $0.43 est. and revenue $295.9M vs. $290.2M consensus; management cited strong demand in its drug‑development product lines as a driver. Biotech firm Bio-Techne beats quarterly estimates on strength in key unit
• Positive Sentiment: Board approved a quarterly cash dividend of $0.08/share (payable Feb. 27), which supports income-oriented holders and signals confidence in cash flow. Bio-Techne Declares Dividend
• Neutral Sentiment: Margins improved and the company described the quarter as “stable” with margin gains — a constructive sign for profitability even as top-line momentum softened. Bio-Techne posts stable Q2 results with margin gains
• Neutral Sentiment: Reported and organic revenue were essentially flat year-over-year, which tempers enthusiasm about growth runway despite product momentum (including recent product launches noted in coverage). Bio-Techne Releases Second Quarter Fiscal 2026 Results
• Negative Sentiment: Valuation and growth expectations likely sap upside: the stock trades at a high P/E and recent analysts’ pieces question whether the rebound priced in enough growth (investors may be taking profits after the post‑earnings reaction). Is Bio-Techne (TECH) Fairly Priced After Recent Share Price Rebound?

Analyst Ratings Changes

Several research firms have commented on TECH. Zacks Research cut Bio-Techne from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 17th. UBS Group boosted their target price on Bio-Techne from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bio-Techne in a research note on Wednesday, January 21st. TD Cowen reaffirmed a “buy” rating on shares of Bio-Techne in a research report on Tuesday, October 14th. Finally, Wells Fargo & Company boosted their target price on Bio-Techne from $59.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $70.57.

Bio-Techne Company Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.